BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+25.41%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$16.7B
AUM Growth
+$16.7B
(+9.1%)
Cap. Flow
-$302M
Cap. Flow
% of AUM
-1.81%
Top 10 Holdings %
Top 10 Hldgs %
86.98%
Holding
128
New
13
Increased
17
Reduced
8
Closed
15
Top Buys
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
$39.8M |
| 2 |
Prime Medicine
PRME
|
$19.1M |
| 3 |
Replimune Group
REPL
|
$18.6M |
| 4 |
ARS Pharmaceuticals
SPRY
|
$17.1M |
| 5 |
Denali Therapeutics
DNLI
|
$13.9M |
Top Sells
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$254M |
| 2 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$92.6M |
| 3 |
Travere Therapeutics
TVTX
|
$43.6M |
| 4 |
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
|
$37.6M |
| 5 |
Altimmune
ALT
|
$18.4M |
Sector Composition
| 1 | Healthcare | 99.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Zymeworks
ZYME
$1.07B
| $13.4M | 0.08% |
1,708,472
| – | – |
|
|
WHWK
52
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$85.3M
| $12.7M | 0.08% |
989,928
| – | – |
|
53
Cabaletta Bio
CABA
$144M
| $12.4M | 0.07% |
1,344,000
+681,937
| +103% | +$6.31M |
|
54
Verastem
VSTM
$585M
| $10.9M | 0.07% |
26,988,898
| – | – |
|
|
55
Altimmune
ALT
$325M
| $10.8M | 0.06% |
653,562
-1,116,119
| -63% | -$18.4M |
|
56
Stoke Therapeutics
STOK
$1.08B
| $10.2M | 0.06% |
1,108,913
+739,586
| +200% | +$6.83M |
|
|
CINC
57
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $9.92M | 0.06% |
807,212
| – | – |
|
58
Vor Biopharma
VOR
$253M
| $9.75M | 0.06% |
1,465,925
| – | – |
|
59
Avidity Biosciences
RNA
$6.12B
| $9.65M | 0.06% |
+434,782
| New | +$9.65M |
|
60
Pacific Biosciences
PACB
$378M
| $9.23M | 0.06% |
1,127,782
| – | – |
|
|
PNT
61
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $8.52M | 0.05% |
1,169,103
| – | – |
|
|
RETA
62
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $8.51M | 0.05% |
223,976
| – | – |
|
63
Summit Therapeutics
SMMT
$17.5B
| $8.5M | 0.05% |
+2,000,000
| New | +$8.5M |
|
64
Veru
VERU
$48.5M
| $8.5M | 0.05% |
1,609,579
| – | – |
|
|
AFMD
65
DELISTED
Affimed
AFMD
| $8.18M | 0.05% |
6,596,830
| – | – |
|
66
Compass Therapeutics
CMPX
$466M
| $7.83M | 0.05% |
+1,557,630
| New | +$7.83M |
|
67
Design Therapeutics
DSGN
$339M
| $7.1M | 0.04% |
692,131
-744,505
| -52% | -$7.64M |
|
68
Biohaven
BHVN
$1.71B
| $6.61M | 0.04% |
+476,190
| New | +$6.61M |
|
69
Vera Therapeutics
VERA
$1.47B
| $6.45M | 0.04% |
333,333
| – | – |
|
70
Alector
ALEC
$282M
| $6.29M | 0.04% |
681,991
+442,763
| +185% | +$4.09M |
|
71
MacroGenics
MGNX
$121M
| $5.99M | 0.04% |
892,579
| – | – |
|
72
Athira Pharma
ATHA
$15.5M
| $5.96M | 0.04% |
1,879,836
+839,002
| +81% | +$2.66M |
|
73
Century Therapeutics
IPSC
$40.4M
| $5.9M | 0.04% |
1,149,340
+778,753
| +210% | +$4M |
|
74
Roivant Sciences
ROIV
$8.6B
| $5.73M | 0.03% |
+716,653
| New | +$5.73M |
|
75
Tango Therapeutics
TNGX
$745M
| $5.44M | 0.03% |
750,000
| – | – |
|